Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of nebivolol on forearm vasodilation, nitric oxide bioavailability, and oxidative stress in patients with stage 1/2 hypertension.

Trial Profile

Effect of nebivolol on forearm vasodilation, nitric oxide bioavailability, and oxidative stress in patients with stage 1/2 hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2010

At a glance

  • Drugs Nebivolol (Primary) ; Metoprolol
  • Indications Hypertension
  • Focus Biomarker; Pharmacodynamics; Registrational
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 06 Jan 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 06 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top